STOCK TITAN

Lineage Cell Therapeutics (LCTX) Stock News, Aug-Nov 2023

LCTX NYSE

Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.

Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags

FAQ

What is the current stock price of Lineage Cell Therapeutics (LCTX)?

Lineage Cell Therapeutics (LCTX) last closed at $0.7719.

What is the market cap of Lineage Cell Therapeutics (LCTX)?

The market cap of Lineage Cell Therapeutics (LCTX) is approximately $195.3M.